Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcy receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcy receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Abstract: A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. An electronic circuit is configured to operate the electrodes. The electronic circuit includes relays connecting the electrodes with a stimulator for performing FES or NMES, and EMG readout circuitry connecting the electrodes with an EMG amplifier. The relays are closed during FES or NMES to connect the stimulator with the electrodes. The relays are open during EMG readout to isolate the stimulator from the EMG amplifier.

Abstract: An example fluid collection assembly (100) includes a sheath (102) and a base (104). The sheath includes a fluid impermeable barrier (106) formed from at least a first panel (108) and a second panel (110). The first panel and the second panel at least partially define a chamber (112) therebetween. The fluid impermeable barrier also defines a fluid outlet (118) at a distal end of the sheath and an opening (114) at a proximal end of the sheath. The sheath also includes at least one porous material (122) disposed in the chamber. The base is permanently secured or configured to be permanently secured to the sheath. The base defines an aperture (124) that is aligned with the opening when the base is permanently attached to the sheath. The base is configured to be secured to a region about a penis of an individual with the aperture positioned over the penis.

Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.

Abstract: A device for functional electrical stimulation (FES), neuromuscular electrical stimulation (NMES), and/or in receiving electromyography (EMG) signals includes a sleeve and electrodes. The sleeve is sized and shaped to be worn on a human arm, and comprises a stretchable fabric The sleeve has a distal end disposed on or adjacent a wrist of the human arm when the sleeve is worn on the human arm and a proximal end opposite from the distal end. The electrodes are secured with the sleeve and positioned to contact skin of the human arm when the sleeve is worn on the human arm. The sleeve may include an inner sleeve contact with the skin and an outer sleeve disposed over the inner sleeve. The inner sleeve has openings in which the electrodes are disposed.

Abstract: A top of stack mounting component. The top of stack mounting component includes a side portion, the side portion being configured to be mounted to a side of a rack; and, an information handling system retention member, the information handing system retention member preventing upward movement of an information handling system as the information handling system is removed from the rack and passes a potential tipping point where more weight of the information handling system is out of the rack as compared to the portion of the weight of the information handling system which is within the rack.

Abstract: The present invention provides VEGF mini-trap molecules and method of treating or preventing angiogenic disorders such as angiogenic eye disorders and cancer.

Abstract: The present disclosure relates to IL12 receptor agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Abstract: Clear nail polish top coat formulations prepared without the use of toxic compounds, such as toluene, are provided. The compositions utilize cellulose acetate butyrate (CAB) as a main resin a discussed are the effects of numerous solvents, plasticizers, co-resins, and/or additives on CAB's solubility. For example, the type and ratio of solvents used are related to the selected CAB grade's molar ratio of butyryl, acetyl, and hydroxyl R-groups. Performances measures include, but are not limited to, transmitted haze, reflected haze, hardness, viscosity, shrinkage, tensile strength, and elastic modulus. Additionally, the effect of filtration on the transmitted haze is also discussed.

Abstract: Multispecific binding molecules (MBMs) comprising at least three antigen binding sites that bind to FGR1c, the GH1 domain of Klotho beta (“KLB”), and the GH2 domain of KLB, pharmaceutical compositions containing the MBMs, methods of using the MBMs and pharmaceutical compositions for treating metabolic diseases, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.

Abstract: Clear nail polish top coat formulations prepared without the use of toxic compounds, such as toluene, are provided. The compositions utilize cellulose acetate butyrate (CAB) as a main resin and discussed are the effects of numerous solvents, plasticizers, co-resins, and/or additives on CAB's solubility. For example, the type and ratio of solvents used are related to the selected CAB grade's molar ratio of butyryl, acetyl, and hydroxyl R-groups. Performances measures include, but are not limited to, transmitted haze, reflected haze, hardness, viscosity, shrinkage, tensile strength, and elastic modulus. Additionally, the effect of filtration on the transmitted haze is also discussed.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.

Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R??. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.